Lupin’s subsidiary -- Lupin Manufacturing Solutions (LMS) has expended its Dabhasa manufacturing facility, marking a significant step toward scaling its peptide building-blocks platform and CRDMO capabilities. The expanded infrastructure features a new block to enhance existing CRDMO capabilities supported by dedicated peptide manufacturing capacity across two additional specialized units. These upgrades will enable advanced development and flexible manufacturing, supporting complex therapeutics and meeting global demand for advanced pharmaceutical solutions.
With global drug development increasingly defined by molecular complexity, such as peptides and biologic ADCs, this expansion reinforces LMS’s capability to consistently supply high-quality peptide building blocks, including protected amino acids.
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1824.00 |
| Dr. Reddys Lab | 1267.80 |
| Cipla | 1355.80 |
| Zydus Lifesciences | 1074.30 |
| Lupin | 2327.50 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: